Evidence map›Paper›PMID 32908982›Full record

ArticlebioRxiv : the preprint server for biology2020

Development of SARS-CoV-2 Nucleocapsid Specific Monoclonal Antibodies.

James S Terry, Loran Br Anderson, Michael S Scherman, Carley E McAlister, Rushika Perera, Tony Schountz, Brian J Geiss

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

James S TerryDepartment of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA.
Loran Br AndersonDepartment of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA.
Michael S SchermanDepartment of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA.
Carley E McAlisterDepartment of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA.
Rushika PereraDepartment of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA.
Tony SchountzDepartment of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA.
Brian J GeissDepartment of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA.

Funding

MERS coronavirus: antagonism of double-stranded RNA induced host response by accessory proteinsR01AI140442 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Susan R Weiss · 2018 to 2026
$5.1M
Mechanism of Flavivirus RNA CappingR01AI132668 · NIAID · COLORADO STATE UNIVERSITY · PI GEISS, BRIAN · 2018 to 2022
$1.9M
A SARS-CoV-2 NFC ePAD BiosensorR01EB031510 · NIBIB · COLORADO STATE UNIVERSITY · PI DANDY, DAVID S, GEISS, BRIAN · 2021 to 2022
$1.0M
NIAID NIH HHS R01 AI132668NIAID NIH HHS R01 AI140442NIBIB NIH HHS R01 EB031510
6 · The paper itself

Abstract

The global COVID-19 pandemic has caused massive disruptions in every society around the world. To help fight COVID-19, new molecular tools specifically targeting critical components of the causative agent of COVID-19, SARS-Coronavirus-2 (SARS-CoV-2), are desperately needed. The SARS-CoV-2 nucleocapsid protein is a major component of the viral replication processes, integral to viral particle assembly, and is a major diagnostic marker for infection and immune protection. Currently available antibody reagents targeting the nucleocapsid protein were primarily developed against the related SARS-CoV virus and are not specific to SARS-CoV-2 nucleocapsid protein. Therefore, in this work we developed and characterized a series of new mouse monoclonal antibodies against the SARS-CoV-2 nucleocapsid protein. The anti-nucleocapsid monoclonal antibodies were tested in ELISA, western blot, and immunofluorescence analyses. The variable regions from the heavy and light chains from five select clones were cloned and sequenced, and preliminary epitope mapping of the sequenced clones was performed. Overall, the new antibody reagents described here will be of significant value in the fight against COVID-19.

Identifiers

PMID32908982
PMCPMC7480041

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.